Chemotherapy and Growth Factor Administration Guidelines

Introduction to Guidelines

The National Comprehensive Cancer Network (NCCN) guidelines recommend that growth factors like filgrastim should not be administered within 24 hours of chemotherapy, and chemotherapy should not be administered less than 24 hours after a filgrastim injection, as growth factors should not be administered within 24 hours of chemotherapy, to minimize risk of adverse events 1
The American College of Clinical Oncology, as referenced by the National Comprehensive Cancer Network, provides clear recommendations regarding the timing of growth factors like filgrastim in relation to chemotherapy, stating that filgrastim should be started 24-72 hours after completion of chemotherapy 1, 2

Filgrastim should be started 24-72 hours after completion of chemotherapy, according to the National Comprehensive Cancer Network guidelines 1, 2
Administration of growth factors on the same day as chemotherapy is not recommended, as stated by the National Comprehensive Cancer Network 1

Growth factors stimulate proliferation of myeloid progenitor cells, and administering chemotherapy too soon after growth factor administration could potentially increase toxicity to rapidly dividing cells stimulated by the growth factor, reduce the efficacy of the growth factor in preventing neutropenia, and increase risk of adverse events 1

Consider using pegfilgrastim, which requires only one administration per chemotherapy cycle, as an alternative to filgrastim, according to the Journal of Clinical Oncology 2

If carfilzomib must be given less than 24 hours after filgrastim, monitor closely for signs of increased toxicity, watch for respiratory symptoms, and monitor complete blood counts to assess neutrophil response, as recommended by the National Comprehensive Cancer Network 1